ARS Pharmaceuticals (SPRY) Other Gross PP&E Adjustments (2021 - 2025)
ARS Pharmaceuticals (SPRY) has disclosed Other Gross PP&E Adjustments for 5 consecutive years, with -$3.3 million as the latest value for Q4 2025.
- Quarterly Other Gross PP&E Adjustments fell 142.12% to -$3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.7 million through Sep 2025, down 13.23% year-over-year, with the annual reading at -$3.3 million for FY2025, 142.12% down from the prior year.
- Other Gross PP&E Adjustments hit -$3.3 million in Q4 2025 for ARS Pharmaceuticals, down from -$1.7 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $41000.0 in Q1 2024 to a low of -$5.6 million in Q3 2021.
- Historically, Other Gross PP&E Adjustments has averaged -$1.8 million across 5 years, with a median of -$1.4 million in 2024.
- Biggest YoY gain for Other Gross PP&E Adjustments was 117.3% in 2024; the steepest drop was 5010.34% in 2024.
- Year by year, Other Gross PP&E Adjustments stood at -$598000.0 in 2021, then tumbled by 292.47% to -$2.3 million in 2022, then skyrocketed by 50.66% to -$1.2 million in 2023, then fell by 18.31% to -$1.4 million in 2024, then crashed by 142.12% to -$3.3 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for SPRY at -$3.3 million in Q4 2025, -$1.7 million in Q3 2025, and -$2.0 million in Q2 2025.